Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Griguolo

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
Cancer|December 21, 2019
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosisFrancesca Palandri, Massimo Breccia, Massimiliano Bonifacio, et al.
Journal of the National Cancer Institute|May 1, 2019
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Tomás Pascual, Carmine De Angelis, et al.
NPJ Breast Cancer|April 17, 2023
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitorsEmma Zattarin, Daniele Presti, Luigi Mariani, et al.
The Lancet. Oncology|November 5, 2020
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, Valentina Guarneri, Laia Paré, et al.
Breast (Edinburgh, Scotland)|April 28, 2026
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 studyFrancesca Ligorio, Leonardo Provenzano, Giuseppe Fotia, et al.
Breast (Edinburgh, Scotland)|January 31, 2026
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2Giacomo Mazzoli, Leonardo Provenzano, Maria Vittoria Dieci, et al.
The Lancet. Oncology|July 17, 2025
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysisGuillermo Villacampa, Tomás Pascual, Paolo Tarantino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2023
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancerG Villacampa, N M Tung, S Pernas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)Claudio Vernieri, Federico Nichetti, Luca Lalli, et al.
Cancer|January 24, 2023
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemiaElisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Cancer|December 21, 2019
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosisFrancesca Palandri, Massimo Breccia, Massimiliano Bonifacio, et al.
Journal of the National Cancer Institute|May 1, 2019
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Tomás Pascual, Carmine De Angelis, et al.
NPJ Breast Cancer|April 17, 2023
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitorsEmma Zattarin, Daniele Presti, Luigi Mariani, et al.
The Lancet. Oncology|November 5, 2020
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, Valentina Guarneri, Laia Paré, et al.
Breast (Edinburgh, Scotland)|April 28, 2026
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 studyFrancesca Ligorio, Leonardo Provenzano, Giuseppe Fotia, et al.
Breast (Edinburgh, Scotland)|January 31, 2026
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2Giacomo Mazzoli, Leonardo Provenzano, Maria Vittoria Dieci, et al.
The Lancet. Oncology|July 17, 2025
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysisGuillermo Villacampa, Tomás Pascual, Paolo Tarantino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2023
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancerG Villacampa, N M Tung, S Pernas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)Claudio Vernieri, Federico Nichetti, Luca Lalli, et al.
Cancer|January 24, 2023
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemiaElisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla, et al.
Pageof 14